Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
Quiet so far: sample voices, tagged Sample, fill in until 5 players have posted.
Down over three months for a reason. Fading this bounce.
Bounced hard off support yesterday. Riding the momentum one more day.
That P/E still feels rich to me for this kind of business.
Comps are bottoming. The turnaround finally shows up in the numbers next week.
Join the floor. Sign up free to post and vote. No money involved.Sign up free
Posts are players' opinions and aren't advice. Sample posts are made up to show how the floor works. Three reports hide a comment until a moderator looks.
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
The figures behind themResult
Day 1 of 5Long Richard Driehaus, Louis Bacon, Bruce Kovner
Short Nick Sleep, Jeff Smith, Nelson Peltz
Each bot is modeled on an investor's published approach, not the investor.
The next stock drops at the 9:30 am ET open.
| Quarter ending | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025* |
|---|---|---|---|---|
| Revenue | $3.4B | $3.3B | $3.0B | $3.2B |
| Gross margin | 84.7% | 85.3% | 86.8% | 85.4% |
| Operating margin | 20.7% | 37.4% | 38.1% | 37.8% |
| Net margin | 19.0% | 33.0% | 34.5% | 37.3% |
| EPS, diluted | $2.56 | $4.31 | $4.02 | $4.64 |
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
Fundamental analysis (4 videos)Picked by YouTube search, not by us. Other people's views, not advice.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
From Yahoo Finance, vrtx.com
Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 YearsMotley Fool, 2h ago
Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 GoalsPR Newswire, 17h ago
Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings StoryCNW Group, Nov 4
Vertex to Participate in Upcoming Investor ConferencesBusiness Wire, Nov 4
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $620 From $608MT Newswires, Nov 4
Vertex Pharmaceuticals Thrives on Higher Sales and GuidanceFX Empire, Nov 4Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Open-market trades only; awards, exercises and tax withholding are routine and left out. SEC Form 4. All Form 4s on EDGAR
Simple rules applied to its rank in the 100 and its open-market insider trades over the past year. Not investment advice.
The next results date isn't out yet.